Ruthenium anticancer compounds: Challenges and expectations

216Citations
Citations of this article
161Readers
Mendeley users who have this article in their library.

Abstract

Two ruthenium compounds, namely [ImH]trans-[RuCl4(Im)(dmso-S)] (NAMI-A, Im = imidazole) and [IndH] trans-[RuCI4(Ind)2] (KP1019, Ind = indazole) have already completed phase I clinical trials as anticancer agents. They both have properties different from platinum anticancer drugs: for example, NAMI-A is selectively active against metastases of solid tumors. They show that in the field of anticancer metal drugs a new approach, based on targeted therapies, is possible. After a concise history of ruthenium anticancer compounds, this contribution will focus on ruthenium-dmso complexes and, in particular, on NAMI-A. Particular emphasis is given on the challenges that are inherent to this field: how to develop new anticancer ruthenium compounds and how to select new active compounds that manifest their anticancer activity through non-conventional mechanisms. © Schweizerische Chemische Gesellschaft.

References Powered by Scopus

Current status of platinum-based antitumor drugs

1842Citations
N/AReaders
Get full text

From bench to bedside - preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)

929Citations
N/AReaders
Get full text

New metal complexes as potential therapeutics

928Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Fluorescent chemical probes for accurate tumor diagnosis and targeting therapy

719Citations
N/AReaders
Get full text

Arene ruthenium complexes as anticancer agents

609Citations
N/AReaders
Get full text

Recent developments in ruthenium anticancer drugs

546Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Bratsos, I., Jedner, S., Gianferrara, T., & Alessio, E. (2007). Ruthenium anticancer compounds: Challenges and expectations. Chimia, 61(11), 692–697. https://doi.org/10.2533/chimia.2007.692

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 61

62%

Researcher 21

21%

Professor / Associate Prof. 13

13%

Lecturer / Post doc 4

4%

Readers' Discipline

Tooltip

Chemistry 98

84%

Agricultural and Biological Sciences 10

9%

Biochemistry, Genetics and Molecular Bi... 6

5%

Pharmacology, Toxicology and Pharmaceut... 3

3%

Save time finding and organizing research with Mendeley

Sign up for free